🖼
Figure 4 — Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyel
active
paper figure
Created: 2026-04-21T18:29:40
By: paper_figures_tool
Quality:
50%
🔗 External
ID: paper-fig-paper-40988129-4
Figure 4Figure 4
Modelled kinetics of tissue damage markers and complement factor C5 in CSF over 60 days following disease exacerbation. Modelled CSF levels of matrix metalloproteinase-9 (MMP-9), glial fibrillary acidic protein (GFAP), S100 calcium-binding protein B (S100B), neurofilament light chain (NfL) and complement C5 are shown for neuromyelitis optica spectrum disorder (NMOSD) (orange line), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (blue line) and multiple sclerosis (MS) (red line). The x -axis represents days post-exacerbation (0–60 days), with the vertical dashed line indicating the transition from the acute (≤21 days) to the subacute/chronic stage (>22 days). Biomarker concentrations ( y -axis) are plotted in pg/ml, except for C5, which is presented in ng/ml, using a log-transformed scale. Solid lines represent modelled trajectories, and shaded areas denote 95% confidence intervals. Distinct kinetic patterns are observed: MMP-9 remains chronically elevated in
▸Metadata
| pmid | paper-40988129 |
| caption | Modelled kinetics of tissue damage markers and complement factor C5 in CSF over 60 days following disease exacerbation. Modelled CSF levels of matrix metalloproteinase-9 (MMP-9), glial fibrillary aci |
| image_url | https://www.ebi.ac.uk/europepmc/articles/PMC13058455/bin/awaf345f4.jpg |
| paper_title | Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. |
| figure_label | Figure 4 |
| figure_number | 4 |
| _schema_version | 1 |
| source_strategy | pmc_api |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.